TY  - JOUR 
AU  - García de Lucas, M.D.
AU  - Caballero, I.
AU  - Fernández-García, J.C.
AU  - Domínguez-Rodríguez, M.
AU  - Moreno-Moreno, P.
AU  - Jiménez-Millán, A.
AU  - Botana-López, M.
AU  - Avilés, B.
AU  - Merino-Torres, J.F.
AU  - Soto, A.
AU  - Tejera Pérez, Cristina
AU  - Morales, C.
PY  - 2023
SN  - 1664-2392
UR  - http://hdl.handle.net/20.500.11940/21663
AB  - Objectives: Semaglutide is a glucagon-like peptide 1 receptor agonist that improves glycemic control and achieves weight loss in type 2 diabetes (T2D) patients. Subcutaneous (s.c.) semaglutide at 1 mg once weekly (OW) is safe in T2D patients with...
LA  - eng
KW  - Humans
KW  - Diabetes Mellitus, Type 2
KW  - Glycated Hemoglobin
KW  - Renal Insufficiency, Chronic
KW  - Weight Loss
TI  - Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study
DO  - 10.3389/fendo.2023.1240279
T2  - Frontiers in Endocrinology
KW  - AS Ferrol
KW  - CHUF
VL  - 14
ER  -